Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT

Author:

Richards Toby123ORCID,Baikady Ravishankar Rao4ORCID,Clevenger Ben35ORCID,Butcher Anna3ORCID,Abeysiri Sandy23ORCID,Chau Marisa23ORCID,Swinson Rebecca6ORCID,Collier Tim6ORCID,Dodd Matthew6ORCID,Dyck Laura Van6ORCID,Macdougall Iain7ORCID,Murphy Gavin8ORCID,Browne John9ORCID,Bradbury Andrew10ORCID,Klein Andrew11ORCID

Affiliation:

1. Division of Surgery, University of Western Australia, Perth, WA, Australia

2. Institute of Clinical Trial and Methodology, University College London, London, UK

3. Division of Surgery, University College London, London, UK

4. The Royal Marsden NHS Foundation Trust, London, UK

5. Department of Anaesthesia, Royal National Orthopaedic Hospital, Stanmore, UK

6. Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK

7. Department of Renal Medicine, King’s College Hospital, London, UK

8. NIHR Leicester Biomedical Research Centre, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

9. School of Public Health, University College Cork, Cork, Ireland

10. University Department of Vascular Surgery (University of Birmingham), Solihull Hospital, Solihull, UK

11. Department of Anaesthesia and Intensive Care, Royal Papworth Hospital, Cambridge, UK

Abstract

Background Anaemia affects 30–50% of patients before they undergo major surgery. Preoperative anaemia is associated with increased need for blood transfusion, postoperative complications and worse patient outcomes after surgery. International guidelines support the use of intravenous iron to correct anaemia in patients before surgery. However, the use of preoperative intravenous iron for patient benefit has not been assessed in the setting of a formal clinical trial. Objectives To assess if intravenous iron given to patients with anaemia before major abdominal surgery is beneficial by reducing transfusion rates, postoperative complications, hospital stay and re-admission to hospital, and improving quality of life outcomes. Design A multicentre, double-blinded, randomised, controlled, Phase III clinical trial, with 1 : 1 randomisation comparing placebo (normal saline) with intravenous iron (intravenous ferric carboxymaltose 1000 mg). Randomisation and treatment allocation were by a secure web-based service. Setting The study was conducted across 46 hospitals in England, Scotland and Wales between September 2013 and September 2018. Participants Patients aged > 18 years, undergoing elective major open abdominal surgery, with anaemia [Hb level of > 90 g/l and < 120 g/l (female patients) and < 130 g/l (male patients)] who could undergo randomisation and treatment 10–42 days before their operation. Intervention Double-blinded study comparing placebo of normal saline with 1000 mg of ferric carboxymaltose administered 10–42 days prior to surgery. Main outcome measures Co-primary end points were risk of blood transfusion or death at 30 days postoperatively, and rate of blood transfusions at 30 days post operation. Results A total of 487 patients were randomised (243 given placebo and 244 given intravenous iron), of whom 474 completed the trial and provided data for the analysis of the co-primary end points. The use of intravenous iron increased preoperative Hb levels (mean difference 4.7 g/l, 95% confidence interval 2.7 to 6.8 g/l; p < 0.0001), but had no effect compared with placebo on risk of blood transfusion or death (risk ratio 1.03, 95% confidence interval 0.78 to 1.37; p = 0.84; absolute risk difference +0.8%, 95% confidence interval –7.3% to 9.0%), or rates of blood transfusion (rate ratio 0.98, 95% confidence interval 0.68 to 1.43; p = 0.93; absolute rate difference 0.00, 95% confidence interval –0.14 to 0.15). There was no difference in postoperative complications or hospital stay. The intravenous iron group had higher Hb levels at the 8-week follow-up (difference in mean 10.7 g/l, 95% confidence interval 7.8 to 13.7 g/l; p < 0.0001). There were a total of 71 re-admissions to hospital for postoperative complications in the placebo group, compared with 38 re-admissions in the intravenous iron group (rate ratio 0.54, 95% confidence interval 0.34 to 0.85; p = 0.009). There were no differences between the groups in terms of mortality (two per group at 30 days post operation) or in any of the prespecified safety end points or serious adverse events. Conclusions In patients with anaemia prior to elective major abdominal surgery, there was no benefit from giving intravenous iron before the operation. Future work The impact of iron repletion on recovery from postoperative anaemia, and the association with reduced re-admission to hospital for complications, should be investigated. Limitations In the preoperative intravenous iron to treat anaemia in major surgery (PREVENTT) trial, all patients included had anaemia and only 20% had their anaemia corrected before surgery. The definition and causality of iron deficiency in this setting is not clear. Trial registration Current Controlled Trials ISRCTN67322816 and ClinicalTrials.gov NCT01692418. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25 No. 11. See the NIHR Journals Library website for further project information.

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3